Étiquette : cannabidiol

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats, Ewa Kozela et al., 2019

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats Ewa Kozela & Martyna Krawczyk & Tomasz Kos & Ana Juknat & Zvi Vogel & Piotr Popik Molecular Neurobiology, 2019, Doi : 10.1007/s12035-019-01831-2   Abstract Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. The mechanisms of these beneficial effects of CBD are unknown. Here, we examined behavioral effects of CBD in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine (KET) administration. In parallel, we assessed transcriptional changes behind CBD activities in the prefrontal cortex (PFC), the [...]

Lire la suite

Bibliographie : Interactions et antagonisme THC – CBD, Docteur Christian SUEUR, GRECC, mars 2020.

Bibliographie : Interactions et antagonisme THC - CBD   Docteur Christian SUEUR, GRECC, mars 2020.   Les interactions entre le THC et le CBD sur le système endocannabinoide, quant aux effets psychotomimetic (production de "symptomes psychotiques") sont opposés : là où le THC produit préférentiellement de l'anxiété, et des effets "psychotisants", le CBD est plutôt anxiolytique et "antipsychotique". Ces deux phytocannabinoïdes sont "antagonistes", et contribuent, parmi d'autres inter-relations entre les phytocannabinoïdes, les terpènes et les flavonoïdes composant le cannabis, aux "effets d'entourage" fondamentaux, tout autant quant à la production "d'effets indésirables" et de risques pour la santé mentale du consommateur, que dans le cadre de [...]

Lire la suite

Cannabis for pediatric epilepsy : protocol for a living systematic review, Jesse Elliott et al., 2018

Cannabis for pediatric epilepsy : protocol for a living systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Bláthnaid McCoy and George A. Wells Systematic Reviews, 2018, 7, 95 doi : 10.1186/s13643-018-0761-2   Abstract Background : Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life, morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of cannabis use in this population. In this systematic review, we will [...]

Lire la suite

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats, Karina Genaro et al., 2017

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats Karina Genaro, Débora Fabris, Ana L. F. Arantes, Antônio W. Zuardi, José A. S. Crippa and Wiliam A. Prado Frontiers in Pharmacology, June 2017 | Volume 8 | Article 391 doi : 10.3389/fphar.2017.00391   Background : Pain involves different brain regions and is critically determined by emotional processing. Among other areas, the rostral anterior cingulate cortex (rACC) is implicated in the processing of affective pain. Drugs that interfere with the endocannabinoid system are alternatives for the management of clinical pain. Cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa, has been utilized [...]

Lire la suite

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs, Hector Lafuente et al., 2011

Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs Hector LAFUENTE, Francisco J. ALVAREZ, M. Ruth PAZOS, Antonia ALVAREZ, M. Carmen REY-SANTANO, Victoria MIELGO, Xabier MURGIA-ESTEVE, Enrique HILARIO, and Jose MARTINEZ-ORGADO Pediatric Research, 2011, 70, 272–277. ABSTRACT : Newborn piglets exposed to acute hypoxia-ischemia (HI) received i.v. cannabidiol (HI CBD) or vehicle (HI VEH). In HI VEH, 72 h post-HI brain activity as assessed by amplitudeintegrated EEG (aEEG) had only recovered to 42 9% of baseline, near-infrared spectroscopy (NIRS) parameters remained lower than normal, and neurobehavioral performance was abnormal (27.8 2.3 points, normal 36). [...]

Lire la suite

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study, Khalid A. Jadoon et al., 2017

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study Khalid A. Jadoon, Garry D. Tan, and Saoirse E. O’Sullivan JCI Insight, 2017, 2, (11), e93760 Doi : 10.1172/jci.insight.93760   BACKGROUND. Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. Preclinical studies show CBD has numerous cardiovascular benefits, including a reduced blood pressure (BP) response to stress. The aim of this study was to investigate if CBD reduces BP in humans. METHODS. Nine healthy male volunteers were given 600 mg of CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. Cardiovascular parameters were monitored using [...]

Lire la suite

Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen-glucose deprivation via PPARγ and 5- HT1A receptors, William H Hind et al., 2016.

Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors William H Hind, Timothy J England and Saoirse E O’Sullivan British Journal of Pharmacology, 2016, 173, 815–825. Doi : 10.1111/bph.13368   BACKGROUND AND PURPOSE In vivo and in vitro studies have demonstrated a protective effect of cannabidiol (CBD) in reducing infarct size in stroke models and against epithelial barrier damage in numerous disease models. We aimed to investigate whether CBD also affects blood–brain barrier (BBB) permeability following ischaemia. EXPERIMENTAL APPROACH Human brain microvascular endothelial cell (HBMEC) and human astrocyte co-cultures modelled the BBB. Ischaemia was modelled by oxygen–glucose deprivation (OGD) [...]

Lire la suite

Is there a role for cannabidiol in psychiatry ?, Julia Machado Khoury et al., 2017

Is there a role for cannabidiol in psychiatry ? Julia Machado Khoury , Maila de Castro Lourenço das Neves, Marco Antônio Valente Roque, Daniela Alves de Brito Queiroz , Andre Augusto Corrêa de Freitas, Angelo de Fatima, Fabrıcio Moreira and Frederico Duarte Garcia The World Journal of Biological Psychiatry, 2017, 16 p. Doi : 10.1080/15622975.2017.1285049   ABSTRACT Objectives : Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic [...]

Lire la suite

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses, Will Lawn et al., 2016

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Will Lawn, Tom P. Freeman, Rebecca A. Pope, Alyssa Joye, Lisa Harvey, Chandni Hindocha, Claire Mokrysz, Abigail Moss, Matthew B. Wall, Michael A.P. Bloomfield, Ravi K. Das, Celia J.A. Morgan, David J. Nutt, H. Valerie Curran Psychopharmacology, 2016, 233, 3537–3552 Doi : 10.1007/s00213-016-4383-x   Abstract Rationale : Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and [...]

Lire la suite